An Open-Label, Single-Dose, Randomized, 3-Period, Crossover Study to Evaluate the Pharmacokinetic Dose Proportionality of Canagliflozin of 50, 100, and 300 mg Under Fasted Conditions in Healthy Subjects.

Trial Profile

An Open-Label, Single-Dose, Randomized, 3-Period, Crossover Study to Evaluate the Pharmacokinetic Dose Proportionality of Canagliflozin of 50, 100, and 300 mg Under Fasted Conditions in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jul 2015

At a glance

  • Drugs Canagliflozin (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Most Recent Events

    • 09 Sep 2011 Actual end date Aug 2011 added as reported by ClinicalTrials.gov.
    • 09 Sep 2011 Actual initiation date changed from Jun 2011 to May 2011 as reported by ClinicalTrials.gov.
    • 09 Sep 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top